Sirna, GlaxoSmithKline to pursue RNAi-based therapeutics

By Lisa Kerner

Erie, Pa., May 4 - Sirna Therapeutics, Inc. and GlaxoSmithKline will pursue RNAi-based therapeutics against chronic obstructive pulmonary disease and allergic rhinitis as part of their multi-year collaboration.

Sirna will provide GlaxoSmithKline with siRNAs against targets, according to a news release.

For its part, GlaxoSmithKline assumes all responsibility for the further preclinical and clinical development of compounds emerging from the collaborative programs.

Short interfering RNA (siRNA) compounds down regulate the expression of proteins responsible for viral replication and pathogenesis.

Located in San Francisco, Sirna Therapeutics is a clinical-stage biotechnology company developing RNAi-based therapies for serious diseases and conditions.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.